June 21 (Reuters) - Biophytis ALBPS.PA :
* ANNOUNCED ON SATURDAY NEW CONVERTIBLE BOND FINANCING FOR
UP TO
€32 MILLION WITH ATLAS AND DRAWING OF 2 TRANCHES UNDER 2020
ATLAS CONTRACT FOR €6 MILLION
* THIS LINE OF FINANCING WILL BE USED FOR FURTHER CLINICAL
DEVELOPMENT OF SARCONEOS (BIO101) IN SARCOPENIA FOLLOWING SARA
PHASE 2 RESULTS AND FOR NEXT DEVELOPMENT STEPS OF PRODUCT IN
COVID-19 FOLLOWING COVA PHASE 2-3 RESULTS
* ISSUANCE OF 240 ORNANE BONDS, FOR A TOTAL AMOUNT OF €6
MILLION
UNDER EXISTING CONVERTIBLE BOND AGREEMENT WITH ATLAS
* ORNANE WILL HAVE PAR VALUE OF €25 000 EUROS
* ORNANE WILL NOT BEAR INTEREST AND WILL HAVE 24-MONTH
MATURITY
FROM ISSUANCE
Source text for Eikon: urn:newsml:reuters.com:*:nNDLqGSpq
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))